United States Live Attenuated Vaccines Market 2025 | Explore High-Growth Trends, Competitive Landscape & Expansion Opportunities

Market Size and Growth

The global live attenuated vaccines market reached US$ 16.80 Billion in 2023, with a rise of US$ 17.82 Billion in 2024 and is expected to reach US$ 31.56 Billion by 2033, growing at a CAGR of 6.6% during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ In August 2025, Novavax's NuvaxovidTM vaccine, a protein-based, non-mRNA COVID-19 vaccine, was approved in the U.S. for the 2025-2026 vaccination season. This approval marks a significant milestone in diversifying vaccine platforms available to the public.

✅ In July 2025, Public Health Vaccines (PHV), a U.S.-based biotech company, received $17.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). This grant supports mid-stage human trials of PHV02, a live-attenuated vaccine candidate against the Nipah virus, one of the world's most deadly pathogens.

✅ In May 2025, the U.S. Department of Health and Human Services announced a $500 million initiative aimed at developing universal vaccine technology. This project, dubbed "Generation Gold Standard," seeks to create vaccines capable of targeting multiple strains of various viruses, including influenza and coronaviruses.

Japan: Recent Industry Developments

✅ In August 2025, Takeda Pharmaceutical Company received a milestone payment following the approval of Novavax's NuvaxovidTM vaccine in Japan. This collaboration highlights the growing international partnerships in vaccine development and distribution.

✅ In June 2025, Japan's Ministry of Health, Labour and Welfare approved LC16m8, the world's only mpox vaccine currently authorized for use in children. This approval underscores Japan's commitment to advancing vaccine options for all age groups.

✅ In May 2025, the University of Tokyo and the Japan Institute for Health Security launched a project focusing on a "singly replicating vaccine" against seasonal influenza. Unlike traditional live-attenuated vaccines, this new modality involves a virus with restricted replicative ability, aiming to enhance safety and efficacy.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/live-attenuated-vaccines-market?sb

Live Attenuated Vaccines contain weakened forms of pathogens that can replicate without causing disease. They stimulate a strong and long-lasting immune response, providing effective protection against infections such as measles, mumps, rubella, and chickenpox while mimicking natural immunity.

Recent Mergers and acquisitions:

United States: Recent M&A Activity
✅ In July 2025, Sanofi announced plans to acquire U.S.-based Blueprint Medicines for up to $9.5 billion. This acquisition aims to enhance Sanofi's oncology portfolio with Blueprint's commercial-stage drug, Ayvakit, and two clinical candidates in inflammation. The deal is expected to close in Q4 2025, subject to regulatory approvals.

✅ In June 2025, BioNTech agreed to acquire CureVac in an all-stock deal valued at approximately $1.25 billion. This strategic move aims to bolster BioNTech's capabilities in developing mRNA-based cancer immunotherapies, reflecting its long-term focus on oncology beyond its COVID-19 vaccine success in partnership with Pfizer.

Japan: Recent M&A Activity
✅ In July 2025, Sanofi expanded its respiratory vaccine portfolio by acquiring UK-based biotech firm Vicebio for $1.15 billion upfront, with potential milestone payments of up to $450 million. The acquisition includes early-stage combination vaccine candidates for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as access to Vicebio's "Molecular Clamp" technology.

Key Players:

-> GlaxoSmithKline Plc, Merck & Co., Inc., Johnson & Johnson, Sanofi, CSL Limited, Serum Institute of India Pvt. Ltd., AstraZeneca, Bavarian Nordic Inc., BioDiem, and Bharat Biotech, among others.

Growth Forecast Projected:

The Global Live Attenuated Vaccines Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Live Attenuated Vaccines Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=live-attenuated-vaccines-market

Key Segments:

➥ By Type: Viral, Bacterial
➥ By Development: Tissue Culture, Live Animals, Embryonated Eggs
➥ By End-User: Hospitals and Clinics, Research Institutes, Healthcare Centers, Others

Regional Analysis for Live Attenuated Vaccines Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Live Attenuated Vaccines producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Live Attenuated Vaccines revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/live-attenuated-vaccines-market?sb

FAQ

What is the current size of the Live Attenuated Vaccines Market?

A: In 2024, the Live Attenuated Vaccines Market was valued at US$ 17.82 Billion , reflecting its strong industry presence.

Q2: How large is the Live Attenuated Vaccines Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Live Attenuated Vaccines Market will grow to around US$ 31.56 Billion , demonstrating significant expansion.

Q3: What is the growth rate of the Live Attenuated Vaccines Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.6% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.